These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36820983)

  • 1. Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.
    Bingham CO; Black S; Shiff NJ; Xu S; Langholff W; Curtis JR
    Rheumatol Ther; 2023 Jun; 10(3):659-678. PubMed ID: 36820983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.
    Curtis JR; Chakravarty SD; Black S; Kafka S; Xu S; Langholff W; Parenti D; Greenspan A; Schwartzman S
    Rheumatol Ther; 2021 Dec; 8(4):1551-1563. PubMed ID: 34417735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study.
    Broadwell A; Schechtman J; Conaway D; Kivitz A; Shiff NJ; Black S; Xu S; Langholff W; Schwartzman S; Curtis JR
    BMC Rheumatol; 2023 Mar; 7(1):5. PubMed ID: 36973741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry.
    Tesser J; Lin I; Shiff NJ; Chakravarty SD; Schmajuk G; Hammam N; Desai S
    Clin Rheumatol; 2022 Aug; 41(8):2319-2327. PubMed ID: 35312895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.
    Orbai AM; Coates LC; Deodhar A; Helliwell PS; Ritchlin CT; Leibowitz E; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Jiang Y; Liu Y; Han C
    Patient; 2022 Nov; 15(6):657-668. PubMed ID: 35768650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
    Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
    J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives.
    Bartlett SJ; Gutierrez AK; Andersen KM; Bykerk VP; Curtis JR; Haque UJ; Orbai AM; Jones MR; Bingham CO
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):588-597. PubMed ID: 33166066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.
    Ellis LA; Malangone-Monaco E; Varker H; Stetsovsky D; Kubacki M; DeHoratius RJ; Kafka S
    Clinicoecon Outcomes Res; 2019; 11():99-110. PubMed ID: 30679916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.
    Bray VJ; Broadwell A; Baraf HSB; Black S; Brady BL; Tkacz J; Yarngo L; DeHoratius RJ
    Drugs R D; 2018 Sep; 18(3):211-219. PubMed ID: 30054896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis.
    Beaumont JL; Davis ES; Curtis JR; Cella D; Yun H
    J Rheumatol; 2021 Aug; 48(8):1239-1242. PubMed ID: 33722955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry.
    Rahman P; Baer P; Keystone E; Choquette D; Thorne C; Haraoui B; Chow A; Faraawi R; Olszynski W; Kelsall J; Rampakakis E; Lehman AJ; Nantel F
    BMC Rheumatol; 2020; 4():46. PubMed ID: 32968710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
    Husni ME; Kavanaugh A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Harrison DD; Han C
    Value Health; 2020 Oct; 23(10):1286-1291. PubMed ID: 33032771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis.
    Bingham Iii CO; Gutierrez AK; Butanis A; Bykerk VP; Curtis JR; Leong A; Lyddiatt A; Nowell WB; Orbai AM; Bartlett SJ
    J Patient Rep Outcomes; 2019 Feb; 3(1):14. PubMed ID: 30790155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
    Curtis JR; Xie F; Kay J; Kallich JD
    Arthritis Res Ther; 2019 Dec; 21(1):285. PubMed ID: 31831064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P; Fleischmann RM; Doyle MK; Strusberg I; Durez P; Nash P; Amante E; Churchill M; Park W; Pons-Estel B; Xu W; Xu S; Wu Z; Hsia EC
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.